25. Watson J. The significance of the paucity of sickle cells in
newborn Negro infants. Am J Med Sci 1948;215:419–23.
26. Marcus SJ, Ware RE. Physiologic decline in fetal hemoglobin parameters in infants with sickle cell disease: implications for pharmacological intervention. J Pediatr Hematol
27. Schroeder WA, Powars DR, Kay LM, et al. Beta-cluster haplotypes, alpha-gene status, and hematological data from SS,
SC, and S-beta-thalassemia patients in southern California.
28. Steinberg MH, Voskaridou E, Kutlar A, et al. Concordant
fetal hemoglobin response to hydroxyurea in siblings with
sickle cell disease. Am J Hematol 2003;72:121–6.
29. Ngo D, Bae H, Steinberg MH, et al. Fetal hemoglobin in
sickle cell anemia: genetic studies of the Arab-Indian hap-lotype. Blood Cells Mol Dis 2013;51: 22–6.
30. Galarneau G, Palmer CD, Sankaran VG, et al. Fine-mapping at three loci known to affect fetal hemoglobin
levels explains additional genetic variation. Nat Genet
31. Lettre G, Sankaran VG, Bezerra MA, et al. DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle
cell disease. Proc Natl Acad Sci U S A 2008;105:11869–74.
32. Sankaran VG, Menne TF, Xu J, et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science 2008;322:1839–42.
33. Uda M, Galanello R, Sanna S, et al. Genome-wide association study shows BCL11A associated with persistent fetal
hemoglobin and amelioration of the phenotype of beta-thalassemia. Proc Natl Acad Sci U S A 2008;105:1620–5.
34. Adams RJ, Kutlar A, McKie V, et al. Alpha thalassemia
and stroke risk in sickle cell anemia. Am J Hematol
35. Ballas SK. Effect of alpha-globin genotype on the pathophysiology of sickle cell disease. Pediatr Pathol Mol Med
36. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral
penicillin in children with sickle cell anemia. A randomized
trial. N Engl J Med 1986;314:1593–9.
37. Ballas SK, Talacki CA, Rao VM, Steiner RM. The prevalence of
avascular necrosis in sickle cell anemia: correlation with alpha-thalassemia. Hemoglobin 1989;13:649–55.
38. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing
sickle cell disease: reappraisal of the role of hemolysis in
the development of clinical subphenotypes. Blood Rev
39. Murphy JR, Wengard M, Brereton W. Rheological studies
of Hb SS blood: influence of hematocrit, hypertonicity,
separation of cells, deoxygenation, and mixture with normal cells. J Lab Clin Med 1976;87:475–86.
40. Fabry ME, Kaul DK, Raventos-Suarez C, Chang H, Nagel
RL. SC erythrocytes have an abnormally high intracellular hemoglobin concentration. Pathophysiological consequences. J Clin Invest 1982;70:1315–9.
41. Stuart J, Johnson CS. Rheology of the sickle cell disorders.
Baillieres Clin Haematol 1987;1:747–75.
42. Lionnet F, Hammoudi N, Stojanovic KS, et al. Hemoglobin
sickle cell disease complications: a clinical study of 179
cases. Haematologica 2012;97:1136-41.
43. Adamkiewicz TV, Sarnaik S, Buchanan GR, et al. Invasive
pneumococcal infections in children with sickle cell disease
in the era of penicillin prophylaxis, antibiotic resistance,
and 23-valent pneumococcal polysaccharide vaccination. J
44. Abboud MR, Yim E, Musallam KM, Adams RJ, Investigators
SIS. Discontinuing prophylactic transfusions increases the
risk of silent brain infarction in children with sickle cell
disease: data from STOP II. Blood 2011;118:894–8.
45. Adams RJ. Lessons from the Stroke Prevention Trial in Sickle Cell Anemia (STOP) study. J Child Neurol 2000;15:344–9.
46. Adams RJ, Brambilla DJ, Granger S, et al. Stroke and
conversion to high risk in children screened with transcranial Doppler ultrasound during the STOP study. Blood
47. Lee MT, Piomelli S, Granger S, et al. Stroke Prevention
Trial in Sickle Cell Anemia (STOP): extended follow-up
and final results. Blood 2006;108:847–52.
48. Charache S, Dover GJ, Moore RD, et al. Hydroxyurea: effects on hemoglobin F production in patients with sickle
cell anemia. Blood 1992;79:2555–65.
49. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea
in Sickle Cell Anemia. N Engl J Med 1995;332:1317–22.
50. Charache S. Mechanism of action of hydroxyurea in the
management of sickle cell anemia in adults. Semin Hematol 1997;34: 15–21.
51. Steinberg MH, McCarthy WF, Castro O, et al. The risks and
benefits of long-term use of hydroxyurea in sickle cell anemia: A 17. 5 year follow-up. Am J Hematol 2010;85:403–8.
52. Noguchi CT, Rodgers GP, Serjeant G, Schechter AN. Levels
of fetal hemoglobin necessary for treatment of sickle cell
disease. N Engl J Med 1988;318:96–9.
53. Powars DR, Weiss JN, Chan LS, Schroeder WA. Is there a
threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia? Blood 1984;63:921–6.
54. Maier-Redelsperger M, de Montalembert M, Flahault A,
et al. Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients.
The French Study Group on Sickle Cell Disease. Blood
55. Steinberg MH, Chui DH, Dover GJ, et al. Fetal hemoglobin
in sickle cell anemia: a glass half full? Blood 2014;123:481–
56. Adragna NC, Fonseca P, Lauf PK. Hydroxyurea affects cell
morphology, cation transport, and red blood cell adhesion
in cultured vascular endothelial cells. Blood 1994;83:553–
57. Bridges KR, Barabino GD, Brugnara C, et al. A multiparam-eter analysis of sickle erythrocytes in patients undergoing
hydroxyurea therapy. Blood 1996;88:4701–10.
58. Jiang J, Jordan SJ, Barr DP, et al. In vivo production of nitric oxide in rats after administration of hydroxyurea. Mol
59. Ware RE. How I use hydroxyurea to treat young patients
with sickle cell anemia. Blood 2010;115:5300– 11.
60. Yates AM, Dedeken L, Smeltzer MP, et al. Hydroxyurea
treatment of children with hemoglobin SC disease. Pediatr
Blood Cancer 2013;60:323–5.
61. Barbosa CG, Aleluia AC, Pacheco AP, et al. Genetic modulation of HbF in Brazilians with HbSC disease and sickle
cell anemia. Am J Hematol 2013;88:923–4.
62. Hsieh MM, Kang EM, Fitzhugh CD, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N